Revvity Debuts Inaugural ESG Report
26 Ottobre 2023 - 2:00PM
Business Wire
Revvity, Inc. (NYSE: RVTY) today unveils its inaugural 2023
Environmental, Social and Governance (ESG) Report. An in-depth
overview of the Company’s ESG strategy, initiatives and
performance, the report showcases the Company’s deepening
commitment to driving more sustainable solutions, along with a
culture of transparency, empowerment and inclusivity.
“Revvity’s ESG program and goals boldly represent what we’re all
about – ensuring that every day we are working to be better by not
only helping advance science, but also doing so in a way that
improves lives and the environment,” said Prahlad Singh, president
and chief executive officer at Revvity. “With Revvity still in its
infancy, it’s important we establish ambitious, yet realistic, ESG
goals that will guide our progress and ensure accountability as we
look to drive a positive impact on the world.”
Key goals highlighted in the report include:
- Achieving a 50% reduction of the Company’s Scope 1 and 2
greenhouse gas emissions by 2033
- Reaching net carbon neutrality by 2040
- Achieving 40% non-hazardous waste landfill diversion by
2027
- Maintaining greater than 40% female representation in
leadership positions
- Achieving greater than 75% employee satisfaction
- Further evaluating and implementing gender pay equality
commitments over the next 12 months
To learn more about Revvity’s ESG commitments and progress visit
esg.revvity.com.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000
employees, Revvity serves customers across pharmaceutical and
biotech, diagnostic labs, academia and governments. It is part of
the S&P 500 index and has customers in more than 190
countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube,
Facebook and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026749816/en/
Investor Relations: Steve Willoughby
steve.willoughby@revvity.com
Media Relations: Chet Murray (781) 663-5719
chet.murray@revvity.com
Grafico Azioni Revvity (NYSE:RVTY)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Revvity (NYSE:RVTY)
Storico
Da Giu 2023 a Giu 2024